A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China
Status:
Recruiting
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1/2a, open-label, multi-center study of JAB-3068 in Patients with advanced
solid tumors.This study has two phases: dose escalation phase and dose expansion phase.